U.S. Markets closed

Veru Inc. (VERU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.36-1.43 (-16.33%)
At close: 4:00PM EDT

7.36 +0.01 (0.07%)
After hours: 4:12PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.79
Open8.60
Bid7.35 x 2900
Ask7.36 x 2200
Day's Range7.30 - 8.70
52 Week Range2.30 - 24.57
Volume3,280,998
Avg. Volume4,096,651
Market Cap576.364M
Beta (5Y Monthly)0.74
PE Ratio (TTM)319.78
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target EstN/A
  • Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?

    Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
    Benzinga

    Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

    Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors. Data will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021. The subset of patients includes those who were heavily pretreated with estrogen-blocking agents and chemotherapy with an average of 3 prior lines of therapy in the metastatic setting and had tumor progression on a CDK 4/6 inhibitor before receiving enobosarm. Enobosarm treatment in evaluable patients who had progressed following treatment with an estrogen-blocking agent and CDK 4/6 inhibitor (palbociclib) resulted in a clinical benefit rate at 24 weeks of 50% and a best objective tumor response of 30%, including two complete responses and one partial response. The overall mean radiographic progression-free survival for the 9mg dose was ten months. The 9mg dose of enobosarm was selected for the Phase 3 ARTEST study anticipated to start in June. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in AR+ER+HER2- metastatic breast cancer. Price Action: VERU stock moved 26.4% higher at $11 during the premarket trading session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For 0MChiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Veru Inc.'s (NASDAQ:VERU) Stock Price Struggling As A Result Of Its Mixed Financials?
    Simply Wall St.

    Is Veru Inc.'s (NASDAQ:VERU) Stock Price Struggling As A Result Of Its Mixed Financials?

    It is hard to get excited after looking at Veru's (NASDAQ:VERU) recent performance, when its stock has declined 37...